References
Referencesarepublicationsthatsupporttheproducts'biologicalactivity.
FinbergandYoudim(2002)Pharmacologicalpropertiesoftheanti-Parkinsondrugrasagiline;modificationofendogenousbrainamines,reserpinereversal,SEROtonergicanddopaminergicbehaviours.Neuropharmacology431110PMID:12504917
Maruyamaetal(2002)Theanti-parkinsondrug,rasagiline,preventsapoptoticDNAdamageinducedbyperoxynitriteinhumandopaminergicneuroblastomaSH-SY5Ycells.J.NeuralTransm.109467PMID:11956966
YoudimandWeinstock(2002)Molecularbasisofneuroprotectiveactivitiesofrasagilineandtheanti-AlzheimerdrugTV3326[(N-propargyl-(3R)aminoindan-5-YL)-ethylmethylcarbamate].Cell.Mol.Neurobiol.21555PMID:
Keywords:Rasagilinemesylate,supplier,Rasagiline,mesylate,monoamine,oxidases,mao-b,mao,b,inhibitors,inhibits,selective,antiparkinsons,antiparkinsonian,parkinson's,parkinsons,Monoamine,Oxidase,Adrenergic,Related,Compounds,Dopaminergic-Related,5-HT-Related,5-HT3,Receptors,Monoamine,Oxidase,TocrisBioscience